Results 1 to 7 of 7
  1. #1
    Elite
    Join Date
    May 2012
    Posts
    863
    Thanks
    16
    Thanked 69 Times in 59 Posts

    Evista (Raloxifene) from Eli Lilly?

    Has anybody used Evista to manage E2, my Doc has been prescribing me this for my E2, is from the pharmacy Eli Lilly, just wondering what you guys think about it.

  2. #2
    Elite
    Join Date
    May 2012
    Posts
    863
    Thanks
    16
    Thanked 69 Times in 59 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    Guys after searching the net quite of bit this is the most relevant information that I could find about Evista (Raloxifene).

    Manufacturer Eli Lilly & Co. already sells raloxifene, under the brand name Evista, to combat bone-thinning osteoporosis, another disease common after menopause. Armed with the new study of nearly 20,000 women, Lilly now plans to seek Food and Drug Administration approval to market raloxifene as a cancer-preventer, too.

    Both drugs are so-called "selective estrogen response modulators" — they act like the estrogen hormone in some tissues, but like an anti-estrogen in others. Estrogen can fuel certain breast cancers. But by acting like an estrogen in the uterus and bloodstream, tamoxifen causes some rare but serious side effects, increasing users' risk of getting uterine cancer or a life-threatening blood clot.

    Raloxifene is a close chemical relative. The NCI study compared the two, and found that taking either tamoxifen or raloxifene daily for up to five years cut in half women's chances of developing invasive breast cancer.

    Raloxifene causes the same side effects, but not as many: Raloxifene users had 36 percent fewer uterine cancers and 29 percent fewer blood clots, the NCI announced Monday. Raloxifene users also suffered fewer vision-blocking cataracts.

    While the reduction in those side effects was significant, the study also shows how uncommon they are. Thirty-six tamoxifen users developed uterine cancers, compared with 23 raloxifene users. The risk of blood clots was similarly low: 54 tamoxifen users had one in the lung, compared with 35 raloxifene users.

    Still, many candidates for tamoxifen risk-reduction therapy have long avoided it for fear of those side effects, noted Dr. Kathy Albain of Loyola University, a study researcher.

    "Here we have something that's a little less scary," Albain said. "It might tip the scales for a lot of women."

    The new study means no change for pre-menopausal women — there's no data showing whether raloxifene is safe for them, Albain stressed.

    Nor does it mean that tamoxifen users should necessarily switch, she said. Women currently are prescribed tamoxifen for five years, and its breast cancer prevention benefit continues even after they stop taking the drug — as raloxifene's seems to. So a woman already in, say, year 4 of her tamoxifen course with no sign of side effects probably has little to gain by switching, she explained.

    But that's a question researchers were girding for as they spent Monday notifying study participants of the results.

    One puzzle: While raloxifene was equally effective in blocking invasive breast cancer, it didn't protect quite as well as tamoxifen against noninvasive types of breast cancer such as ductal carcinoma in situ, noted Dr. Len Lichtenfeld of the American Cancer Society.

    That type of tumor isn't life-threatening and shouldn't water down the overall message of raloxifene's benefit, said Dr. Victor Vogel of the University of Pittsburgh, who oversaw the study's design.

    Among postmenopausal women, who's at high risk? Most of the study participants had a 4 percent chance of getting breast cancer within five years — because of advanced age, a close relative with the disease, never having a child or having one late in life, or other well-known risk factors that women can calculate on a government Web site: http://cancer.gov/bcrisktool.

    In simpler terms, for every 1,000 of those women, doctors expected 40 to develop breast cancer within five years if they did nothing, but taking one of the drugs cut that number to 20, Ford explained.

  3. #3
    Elite Christosterone's Avatar
    Join Date
    Oct 2012
    Location
    Texas
    Posts
    1,026
    Thanks
    16
    Thanked 16 Times in 16 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    I used it for pct last cycle...it was great, it also doesn't caused the mental clouding that tamoxifene has been reported to cause

  4. #4
    Senior Member ripped_one's Avatar
    Join Date
    Dec 2011
    Posts
    192
    Thanks
    0
    Thanked 3 Times in 2 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    Raloxifene isn't bad for pct or using as a serm for gyno prevention but it isn't as effective as toremifene or tamox.

    If your doc is using it to control e2 he is off. It doesn't lower estrogen, it inhibits the action of estrogen at the receptor. I would use arimidex or exemestane for that.

  5. #5
    Elite Christosterone's Avatar
    Join Date
    Oct 2012
    Location
    Texas
    Posts
    1,026
    Thanks
    16
    Thanked 16 Times in 16 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    Originally Posted by ripped_one View Post
    Raloxifene isn't bad for pct or using as a serm for gyno prevention but it isn't as effective as toremifene or tamox.

    If your doc is using it to control e2 he is off. It doesn't lower estrogen, it inhibits the action of estrogen at the receptor. I would use arimidex or exemestane for that.
    There are studies that report that raloxifene is more effective at removing gyno :

    1: J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

    Comment in:

    * J Pediatr. 2005 Apr;146(4):576; author reply 576-7.
    * J Pediatr. 2005 Apr;146(4):576; author reply 576-7.

    Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
    Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
    Department of Pediatrics, University of Ottawa, Ontario, Canada.

    OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifene in the medical management of persistent pubertal gynecomastia.

    STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).

    RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

    CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

    PMID: 15238910 [PubMed - indexed for MEDLINE]

  6. #6
    Senior Member ripped_one's Avatar
    Join Date
    Dec 2011
    Posts
    192
    Thanks
    0
    Thanked 3 Times in 2 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    Originally Posted by Christosterone View Post
    There are studies that report that raloxifene is more effective at removing gyno :

    1: J Pediatr. 2004 Jul;145(1):71-6. Related Articles, Links

    Comment in:

    * J Pediatr. 2005 Apr;146(4):576; author reply 576-7.
    * J Pediatr. 2005 Apr;146(4):576; author reply 576-7.

    Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.
    Lawrence SE, Faught KA, Vethamuthu J, Lawson ML.
    Department of Pediatrics, University of Ottawa, Ontario, Canada.

    OBJECTIVES: To assess the efficacy of the anti-estrogens tamoxifen and raloxifene in the medical management of persistent pubertal gynecomastia.

    STUDY DESIGN: Retrospective chart review of 38 consecutive patients with persistent pubertal gynecomastia who presented to a pediatric endocrinology clinic. Patients received reassurance alone or a 3- to 9-month course of an estrogen receptor modifier (tamoxifen or raloxifene).

    RESULTS: Mean (SD) age of treated subjects was 14.6 (1.5) years with gynecomastia duration of 28.3 (16.4) months. Mean reduction in breast nodule diameter was 2.1 cm (95% CI 1.7, 2.7, P <.0001) after treatment with tamoxifen and 2.5 cm (95% CI 1.7, 3.3, P <.0001) with raloxifene. Some improvement was seen in 86% of patients receiving tamoxifen and in 91% receiving raloxifene, but a greater proportion had a significant decrease (>50%) with raloxifene (86%) than tamoxifen (41%). No side effects were seen in any patients.

    CONCLUSION: Inhibition of estrogen receptor action in the breast appears to be safe and effective in reducing persistent pubertal gynecomastia, with a better response to raloxifene than to tamoxifen. Further study is required to determine that this is truly a treatment effect.

    PMID: 15238910 [PubMed - indexed for MEDLINE]
    Well I'll be damned.. thanks for the info man. I guess ralox would be better to use on cycle for gyno prevention than tamox after all.

    I do know tamox and torem work better for hpta recovery though. http://www.ergo-log.com/nolvabest.html

    What dose ralox did you use?

  7. #7
    Elite Christosterone's Avatar
    Join Date
    Oct 2012
    Location
    Texas
    Posts
    1,026
    Thanks
    16
    Thanked 16 Times in 16 Posts

    Re: Evista (Raloxifene) from Eli Lilly?

    Granted, this is just for gyno, dealing with cancer prevention, it's a little different, I was taking the 60 mg dose, or would take two of the, at beginning of pct. Raloxifene isn't as readily available. But it doesn't cause as many blood clots, cataracts, or mental cloudiness, there are other benefits with raloxifene, such as increased bone density

Similar Threads

  1. Kill my raloxifene gyno cycle.
    By gymrat827 in forum Anabolic Steroid Cycle Discussion
    Replies: 55
    Last Post: 09-24-2017, 04:37 PM
  2. Has anyone used Raloxifene or toremiphene in place of nolva on pct?
    By Lt. Aldo Raine in forum Post Cycle Therapy
    Replies: 15
    Last Post: 04-07-2014, 09:25 PM
  3. Raloxifene and pct question.
    By Azog in forum Post Cycle Therapy
    Replies: 4
    Last Post: 01-13-2013, 05:05 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •